Amgen, Inc.

T.C. has consulted/advised/spoken for ASCO Post, AstraZeneca, Bio Ascend, Bristol Myers Squibb, Clinical Care Options, Daiichi Sankyo, Genentech, IDEOlogy Health, Medical Educator Consortium, Medscape, Merck, OncLive, oNKo-innate, PEAK Medicals, PeerView, Pfizer, Physicians’ Education Resource, RAPT Therapeutics, Regeneron, Targeted Oncology. W.N.W.Jr. has consulted/advised/spoken for Amgen, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Daiichi-Sankyo, Eli Lilly, Genentech/Roche, Ipsen, Janssen, Merck, MSD, Novartis, Pfizer, Sanofi-Aventis, Takeda, United Medical.

Amgen’s MariTide showed 20% weight loss in non-diabetic and 17% in diabetic participants over 52 weeks, with no plateau observed. MariTide, a GLP-1 receptor agonist and GIPR antagonist, offers monthly dosing via a handheld device, improving cardiometabolic parameters without significant adverse effects. Amgen plans to initiate Phase III trials, targeting obesity and related conditions.

Tonix Pharmaceuticals appoints Bradley Raudabaugh as VP of Marketing and Errol Gould as VP of Medical Affairs to support the launch of TNX-102 SL for fibromyalgia. The NDA for TNX-102 SL was submitted to the FDA in October 2024, with an expected decision in 2025, potentially marking the first new drug for fibromyalgia in over 15 years.

Phase 3 trial data for biosimilar CT-P41 (Celltrion) in postmenopausal osteoporosis showed equivalence to denosumab in efficacy, pharmacodynamics, pharmacokinetics, and safety, with well-tolerated transitions from reference product to biosimilar.

The global Combination Antibody Therapy market is projected to grow from $178.1B in 2023 to $443B by 2030, driven by cancer prevalence, immunotherapy advancements, and personalized medicine. The report by ResearchAndMarkets.com offers insights into market trends, drivers, and forecasts.

Scrip’s weekly podcast covers Trump’s FDA threat, Amgen’s unclear MariTide Phase II data, Roche’s Poseida acquisition, Roche CMO’s biotech insights, and potential impacts of Trump 2.0 on India.

November 2024 saw significant advancements in endocrinology, including phase 2 trial results for MariTide, a bispecific GLP-1 and GIPR agonist showing up to 20% weight loss; a study suggesting over half of US adults qualify for semaglutide treatment; BPROAD trial findings emphasizing cardiovascular benefits of intensive blood pressure control in type 2 diabetes; an FDA advisory committee vote against sotagliflozin in type 1 diabetes; and new data on semaglutide reducing knee osteoarthritis pain in obese patients. Additionally, five new episodes of 'Diabetes Dialogue' provided expert insights into technology, trial data, and real-world perspectives in diabetes care.

DelveInsight's 'Graft versus host disease Pipeline Insight 2024' covers 60+ companies and 65+ pipeline drugs, including clinical and nonclinical stage products, with a focus on therapeutics assessment by product type, stage, route of administration, and molecule type. Key companies and promising therapies in development are highlighted.

Amgen's MariTide, an experimental obesity treatment, showed a 20% weight loss in trials but common side effects like nausea and vomiting limit its competitiveness. Eli Lilly and Novo Nordisk's next-gen drugs, potentially achieving 25% weight loss, dominate the market. MariTide's antibody-linked peptide mechanism offers durability but faces Phase III trials. Amgen's stock fell 12.3% post-report, reflecting market skepticism.

Invest better with The Motley Fool's premium services for stock recommendations and portfolio guidance.